Spots Global Cancer Trial Database for primary drug resistance of oxitinib
Every month we try and update this database with for primary drug resistance of oxitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | NCT06436144 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Osimertinib | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | NCT06436144 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Osimertinib | 18 Years - 80 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |